| Disease | Micro RNA | Tissue/ Cell line | MicroRNA regulation | Pathway | More Details | References |
|---|---|---|---|---|---|---|
| Pancreatic ductal adenocarcinoma | hsa-miR-323 | Pancreas | Down | TGF-beta signaling pathway | Down-regulation of miR-323 is associated with TGF-beta-induced aggressive phenotypes through modulation of SMAD2 expression in Pancreatic ductal adenocarcinoma. | Wang et al., 2016 |
| Colorectal cancer | hsa-miR-140 | HCT 116 | TGF-beta signaling pathway | Hsa-miR-140 inhibits colorectal carcinoma progression and metastasis through the down-regulation of Smad2, a key player in theTGF-beta signaling pathway. | Zhai et al., 2015 | |
| Colorectal cancer | hsa-miR-140 | HCT 116 | Down | TGF-beta signaling pathway | hsa-miR-140 inhibit CRC progression and metastasis by directly targeting Smad2 which is a key element inTGF-beta signaling pathway. | Zhai et al., 2015 |
| Hepatocellular carcinoma | hsa-miR-148a | Hepatocyte | TGF-beta signaling pathway | Overexpression of miR-148a inhibits the expression of SMAD2 and cancer stem cell-like properties in hepatocellular carcinoma cells throughTGF-beta signaling pathway. | Jiang et al., 2014 |